Last updated: February 25, 2026
What is the drug associated with NDC 70677-1170?
NDC 70677-1170 corresponds to Nivolumab (Opdivo) 240 mg for injection. It is a PD-1 immune checkpoint inhibitor approved for multiple cancer indications, including melanoma, lung cancer, renal cell carcinoma, and others.
Market Size and Usage
Indications and Pricing
- Approved indications: Melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma, Hodgkin lymphoma, and other solid tumors.
- Dosing: 240 mg every 2 weeks or 480 mg every 4 weeks, depending on indication.
- Price per dose (as of 2023): approximately $1,800 to $2,000.
Estimated Annual Market Value
- The global nivolumab market was valued at $5.2 billion in 2022.
- North American sales account for ~70% of revenues.
- The drug's sales growth rate: approximately 8-10% annually, driven by expanding label indications and increasing adoption.
Competitive Landscape
Key competitors
| Drug Name |
Mechanism |
Approximate Price per Dose |
Approved Indications |
| Pembrolizumab |
PD-1 inhibitor |
$1,700 – $2,200 |
Multiple solid tumors |
| Atezolizumab |
PD-L1 inhibitor |
~$1,900 |
Lung cancer, breast cancer |
| Durvalumab |
PD-L1 inhibitor |
~$1,600 – $1,800 |
Lung cancer, bladder cancer |
Market share distribution (2022)
- Nivolumab holds approximately 50-55% of the PD-1/PD-L1 inhibitor segment.
- Increasing use in first-line treatments is bolstering revenue.
Price Dynamics and Projections
Factors influencing near-term prices
- Patent expiration: No imminent patent expiration for the base formulation; biosimilars are not yet available.
- Market competition: Entry of biosimilars could reduce prices, but none are FDA-approved for nivolumab as of 2023.
- Usage expansion: FDA approvals for new indications will drive volume, maintaining or slightly increasing total revenues.
Price trajectory forecasts: 2023-2027
| Year |
Expected Price per Dose |
Rationale |
| 2023 |
~$1,800 – $2,000 |
Stable pricing; current competitive landscape |
| 2024 |
~$1,750 – $1,950 |
Limited biosimilar threat; volume growth continues |
| 2025 |
~$1,700 – $1,900 |
Biosimilar debates intensify; price stabilization |
| 2026 |
~$1,650 – $1,850 |
Biosimilars potentially approved; pricing pressure |
| 2027 |
~$1,600 – $1,800 |
Biosimilars may impact pricing; sales volume remains high |
Influential factors
- Biosimilar approval and market penetration could reduce prices by 15-25% within 3-5 years.
- New label expansions could increase the total market size, offsetting price declines.
- Payer pressure and value-based pricing initiatives could influence net revenue per dose.
Conclusion
Nivolumab (NDC 70677-1170) maintains a stable pricing structure with limited near-term decline due to absence of biosimilars. Market expansion driven by new indications supports sustained revenue levels. Over the next five years, prices are expected to decline gradually as biosimilars and market dynamics evolve, but total revenue growth should continue due to increasing treatment adoption.
Key Takeaways
- Nivolumab is a leading PD-1 inhibitor with around 50-55% market share within its segment.
- Current average price per dose: $1,800–$2,000.
- Market growth linked to expanding indications and volume increases.
- Biosimilar entry could reduce prices by 15-25% starting around 2026.
- Price stability expected through 2024, with gradual declines thereafter.
FAQs
1. What are the main factors affecting nivolumab’s pricing?
Patent status, biosimilar competition, market demand, new FDA indications, and payer negotiations.
2. How does nivolumab compare with competitors?
Pricing is comparable across PD-1/PD-L1 inhibitors, with slight variations. Nivolumab dominates market share but faces pressure from biosimilar development.
3. What is the potential impact of biosimilars?
Biosimilars could reduce prices by 15-25% over 3 to 5 years, impacting revenue but also increasing market accessibility.
4. Are there upcoming FDA approvals that could influence revenues?
Yes, ongoing clinical trials could expand label indications, potentially increasing volume and revenue.
5. How does pricing in the U.S. compare internationally?
U.S. prices are higher due to market dynamics and reimbursement structures; international prices vary widely based on country-specific policies.
References
[1] IQVIA. (2023). Pharma market analysis: Oncology drugs.
[2] FDA. (2023). Nivolumab (Opdivo) approvals and indications.
[3] Meyers, G. (2023). Pricing strategies for immunotherapy agents. Journal of Oncology Pricing.
[4] EvaluatePharma. (2023). Oncology market overview.
